mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, has appointed Jurgen Van Broeck as Chief Executive Officer.
 
Broeck, who has served as Global Commercial Director since June 2023, brings experience and a proven track record in the pharmaceutical and biosimilar industries.
 
Prior to his new role, Broeck was at the forefront of mAbxience’s strategic initiatives, overseeing all commercial, business development and market access activities. He has been instrumental in steering the company’s strategic partnering and establishing the growth trajectory of our CDMO services. Under his leadership, mAbxience has enhanced its global presence and continued to excel in delivering accessible, high-quality medicines worldwide.
 
Broeck joined mAbxience with nearly two decades of extensive experience in the healthcare sector, including significant roles at multinational corporations such as Merck and Mundipharma.
 
“I am honored to lead mAbxience in this exciting growth phase of the company as we continue to strive for excellence in everything we do,” said Broeck. “Our mission to provide quality, affordable biological medicines and deliver world-class CDMO services remains at the core of our strategy. I look forward to working closely with our talented team to advance our pipeline, expand our global footprint and become a world-known CDMO for biologics.”